Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.980
-0.030 (-1.00%)
Jan 22, 2025, 2:02 PM EST - Market open
Vistagen Therapeutics Employees
As of March 31, 2024, Vistagen Therapeutics had 40 total employees, including 39 full-time and 1 part-time employees. The number of employees increased by 6 or 17.65% compared to the previous year.
Employees
40
Change (1Y)
6
Growth (1Y)
17.65%
Revenue / Employee
$21,900
Profits / Employee
-$989,125
Market Cap
82.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
VTGN News
- 8 days ago - Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - Business Wire
- 12 days ago - Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - Business Wire
- 2 months ago - Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire
- 2 months ago - Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
- 2 months ago - Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
- 2 months ago - Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - Business Wire
- 3 months ago - Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha